Find uplifting stories about heroes, innovations, and solutions
87 results for "merck"
Merck just agreed to let seven companies make free generic versions of its experimental HIV prevention pill for low and middle-income countries. The pharmaceutical giant isn't waiting for approval—it's planning ahead so millions can access the once-a-month pill as soon as it's ready.
A personalized mRNA cancer vaccine from Merck and Moderna has succeeded in Phase 3 trials, marking a major breakthrough in immunotherapy. The treatment, called intismeran autogene, tailors cancer-fighting instructions to each patient's unique tumor.
A breakthrough cholesterol pill from Merck just proved it works as well as injections, making life-saving heart disease treatment easier than ever. With heart disease still America's number one killer for a century, this daily pill could help 70% of patients who aren't reaching their cholesterol goals.
A personalized cancer vaccine from Merck and Moderna just crushed its first late-stage trial, keeping melanoma patients cancer-free significantly longer than current treatment alone. The breakthrough validates decades of research into custom-made cancer fighters tailored to each patient's unique tumor.
Patient advocates from 30 countries are already calling on Merck to ensure its promising monthly HIV prevention pill reaches everyone who needs it. The treatment could revolutionize HIV prevention by replacing daily pills with a once-a-month option.
A groundbreaking cancer vaccine from Moderna and Merck reduced the chances of melanoma returning after surgery in a major trial with over 1,100 patients. Even the company's own executives didn't believe it would work.
Millions with high cholesterol just got a simpler treatment option. The FDA approved Merck's new pill that could replace regular injections for heart disease prevention.
After a century of failed attempts, a personalized mRNA cancer vaccine has successfully completed late-stage trials in melanoma patients. The treatment trains each person's immune system to fight their unique tumor mutations.
A promising HIV prevention pill could be manufactured for less than $5 per patient annually, making protection accessible to millions worldwide. The experimental drug shows results within 24 hours and could transform HIV prevention in low-income countries.
A personalized cancer vaccine from Moderna and Merck just succeeded in its first large-scale trial, cutting melanoma recurrence rates and bringing hope to thousands. The breakthrough could transform how we treat cancer within the next year.
A personalized mRNA vaccine from Moderna and Merck has shown remarkable five-year results against aggressive skin cancer. The therapy nearly halves the risk of melanoma returning after surgery.
A personalized cancer vaccine from Moderna and Merck just proved it can train your immune system to fight melanoma tumors with pinpoint accuracy. Thousands of patients could benefit within years, with trials already underway for lung, pancreatic, and colon cancers.
Merck and Mayo Clinic are combining artificial intelligence with real patient data to speed up the discovery of breakthrough medicines. The collaboration aims to make drug development faster, smarter, and more likely to succeed.
The FDA just approved a powerful new combination therapy that could help thousands of kidney cancer patients stay cancer-free after surgery. Merck's belzutifan paired with Keytruda offers new hope for those at high risk of their cancer returning.
A personalized mRNA cancer vaccine developed by Moderna and Merck has shown remarkable success in preventing melanoma from returning. The breakthrough sent Moderna's stock soaring 90% and offers new hope for treating cancer beyond COVID vaccines.
Forty talented Ghanaian girls just received scholarships that will cover their education all the way through graduation, removing financial barriers to their dreams. The Merck Foundation's Educating Linda program has now supported over 1,500 schoolgirls across 21 African countries.
Major pharmaceutical companies are replacing animal testing with cutting-edge human tissue models that predict drug safety more accurately. Merck KGaA plans to eliminate most animal tests within a decade.
A personalized mRNA vaccine combined with immunotherapy reduced melanoma recurrence or death by nearly half over five years. The breakthrough treatment, developed by Merck and Moderna, teaches the immune system to recognize and attack cancer cells.
Moderna and Merck just achieved the first successful late-stage trial of an mRNA cancer vaccine for melanoma, opening doors for more affordable universal cancer treatments. The breakthrough validates technology that could one day make fighting cancer as simple as getting a shot.
A personalized mRNA cancer vaccine combined with existing treatment successfully slowed melanoma's return in a groundbreaking late-stage trial. This first-of-its-kind success could open new doors for cancer patients worldwide.
Showing 20 of 87